
    
      This is a multi center, randomized, double blind, placebo controlled, fixed dose study of
      eszopiclone in pediatric subjects 6-17 years of age, inclusive, with ADHD associated
      insomnia. Subjects will be randomized at approximately 1:1:1 to either low dose oral
      eszopiclone (1 mg for children ages 6-11 years, 2 mg for adolescents ages 12-17 years), high
      dose oral eszopiclone (2 mg for children ages 6-11 years, 3 mg for adolescents ages 12-17
      years) or placebo. This study was previously posted by Sepracor Inc. In October 2009,
      Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's
      name was changed to Sunovion Pharmaceuticals Inc.
    
  